China Biopharm Registers High Growth Figures For First Quarter

This article was originally published in PharmAsia News

27 May 2008
News

PharmAsia News @PharmAsiaNews pharmasia@informa.com

Executive Summary

SHANGHAI - China Biopharmaceuticals saw a strong growth in revenues in the first quarter of 2008 on the back of increased sales from its subsidiary Erye Pharmaceuticals. The company released fiscal results for its first quarter ended March 31 on May 16

Already Registered? Sign in to continue reading.

New to Scrip? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

SC068573

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

SC068573

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

China Biopharm Registers High Growth Figures For First Quarter

News

Executive Summary

Related Content

China’s MOH-SFDA Merger: Analysts Weigh In

China’s MOH-SFDA Merger: Analysts Weigh In

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert